Associate Professor Michael Hill
MRC Population Health Research Unit
Supporting Technology, Lead
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Associate Professor Mike Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Mike works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Helicobacter pylori multiplex serology and risk of non-cardia and cardia gastric cancer: a case-cohort study and meta-analysis.
Yao P. et al, (2023), Int J Epidemiol
Diabetes and infectious disease mortality in Mexico City.
Bragg F. et al, (2023), BMJ open diabetes research & care, 11
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.
Chapman D. et al, (2023), Kidney Int
Proteomic profiling identifies novel independent relationships between inflammatory proteins and myocardial infarction.
Valdes-Marquez E. et al, (2023), Eur J Prev Cardiol
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease.
Clarke R. et al, (2023), Circ Res